Conatumumab Explained

Conatumumab (originally AMG-655) is a monoclonal antibody developed for the treatment of cancer. It is a fully human monoclonal agonist antibody directed against the extracellular domain of human TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) receptor 2 (TR-2, death receptor 5) with potential antineoplastic activity.[1] [2] Conatumumab mimics the activity of native TRAIL, binding to and activating TR-2, thereby activating caspase cascades and inducing tumor cell apoptosis. TR-2 is expressed by a variety of solid tumors and cancers of hematopoietic origin.[3] [4]

The drug was developed by Amgen Inc. In 2008, Takeda licensed the drug from Amgen for development in Japan, but discontinued development in 2011.

References

  1. Rosevear HM, Lightfoot AJ, Griffith TS . Conatumumab, a fully human mAb against death receptor 5 for the treatment of cancer . Current Opinion in Investigational Drugs . London, England . 11 . 6 . 688–98 . June 2010 . 20496264 .
  2. Bajaj M, Heath EI . Conatumumab: a novel monoclonal antibody against death receptor 5 for the treatment of advanced malignancies in adults . Expert Opinion on Biological Therapy . 11 . 11 . 1519–24 . November 2011 . 21877997 . 10.1517/14712598.2011.610788 . 28520935 .
  3. http://www.ama-assn.org/ama1/pub/upload/mm/365/conatumumab.pdf Statement On A Nonproprietary Name Adopted By The USAN Council – Conatumumab
  4. http://www.cancer.gov/Templates/drugdictionary.aspx?CdrID=573083 National Cancer Institute: Definition of conatumomab

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Conatumumab".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2025, A B Cryer, All Rights Reserved. Cookie policy.